(NEO) NeoGenomics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NEO) NeoGenomics, Inc. Complete Analysis Pack
See the Bigger Picture
This NeoGenomics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The content shown on this page is a real preview of the actual report, so you can review the format and analysis before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.
Stars
Pharma Services oncology biomarker trials
NeoGenomics, Inc. Pharma Services is a Star: it supports discovery through commercialization, and oncology drug development stayed one of the fastest-growing CRO outsourcing areas through end-2025. The unit benefits from durable demand in biomarker-driven trials, where precision oncology keeps lifting trial complexity and spend. With meaningful scale inside NeoGenomics, it is a clear growth engine, not a niche add-on.
Molecular oncology testing
Molecular oncology testing is a Star for NeoGenomics, Inc. because DNA and RNA-based panels sit at the center of precision oncology and keep shifting demand toward deeper, more complex testing. In FY2025, this category remained a core growth engine as the company pushed higher-value next-generation sequencing and fusion testing across its oncology menu. That mix supports brand strength, pricing power, and share gains in a fast-growing market.
Liquid biopsy and ctDNA
Liquid biopsy and ctDNA are a clear Star for NeoGenomics, Inc., because the segment is growing fast and adoption is still climbing. Inivata-linked capabilities strengthen its reach in MRD and early relapse detection, where ctDNA can be measured at very low variant allele fractions, often below 0.1%. The market is still expanding, so this line has high growth and rising strategic value.
MRD-focused oncology assays
MRD-focused oncology assays are a high-growth niche because they track tiny cancer traces after treatment, not just at diagnosis. In a market where MRD use is expanding across solid tumors and blood cancers, NeoGenomics, Inc. has flagged this as a core future-growth platform, with the biggest value in monitoring response and spotting recurrence earlier.
- Monitors treatment response
- Tracks recurrence risk
- Expands beyond diagnosis
- Supports NeoGenomics growth
Integrated multi-modality cancer testing
NeoGenomics runs 5 testing lanes in one oncology platform: molecular, cytogenetic, FISH, flow, and pathology. That breadth is a clear Star trait, because hospitals and oncologists can keep one vendor across the full workup, and pharma partners get cleaner trial and companion-diagnostic support.
The integrated menu helps raise retention and cross-sell rates across the testing chain, which matters in a fragmented cancer testing market. One platform, more touchpoints, and fewer handoffs.
- 5 modalities under one platform
- Stronger hospital and oncologist stickiness
- Better cross-sell across test types
- Useful for pharma trial support
NeoGenomics’ Precision Oncology Engines Are Firing on All Cylinders
NeoGenomics, Inc. Stars are its Pharma Services, molecular oncology, liquid biopsy/ctDNA, and MRD assays: all sit in fast-growing precision oncology niches and support both clinical testing and pharma demand. The company also benefits from an integrated 5-lane platform, which improves stickiness and cross-sell across oncology workflows.
| Star | Why it matters |
|---|---|
| Pharma Services | Drug development demand |
| Molecular oncology | NGS and fusion growth |
| Liquid biopsy/ctDNA | Fast adoption, MRD use |
| Integrated platform | 5 testing lanes, higher retention |
What is included in the product
Detailed Word Document
NeoGenomics BCG Matrix maps its testing portfolio by growth and share, guiding invest, hold, or divest decisions.
Editable Excel File
BCG matrix for NeoGenomics, Inc. that quickly spots growth and drag areas for faster portfolio decisions
Reference Sources
Provides a traceable source trail for NeoGenomics, Inc. data, helping verify assumptions fast and support confident decisions.
Cash Cows
Clinical Services core lab network
Clinical Services is NeoGenomics’ mature cash engine, with FY2024 revenue of about $615 million and a national network serving hospitals, reference labs, pathologists, and oncologists. Growth is slower than newer tests, but demand is steady and the platform stays essential to recurring oncology testing. That makes it a classic Cash Cow: lower growth, strong scale, and dependable cash flow.
FISH testing
FISH testing is a mature oncology assay, so demand is steadier than next-generation molecular testing. For NeoGenomics, Inc., that makes it a Cash Cow: lower-growth, recurring lab volume that still supports revenue. The test stays useful for targeted cancer markers, so it keeps paying even as newer platforms take share.
Cytogenetics
Cytogenetics is a legacy cash cow for NeoGenomics, with steady demand in cancer diagnostics and long-used lab workflows. It is a mature business, so it is more about supporting stable cash flow than fast growth. That fits a BCG Cash Cow profile: low expansion, but dependable contribution to the company’s operating base.
Flow cytometry
Flow cytometry is a Cash Cow for NeoGenomics, Inc. because it is a core oncology and hematology test used in routine clinical workflows, so demand is steady and repeatable. The service supports margins through high utilization, even if growth is modest versus newer molecular tests.
In NeoGenomics, Inc.’s 2025 reporting, this kind of mature lab volume helps offset more volatile assay lines and keeps the base business stable.
- Steady oncology test demand
- Embedded in routine workflows
- Modest growth, reliable revenue
- Supports lab margin stability
Immunohistochemistry and morphologic analysis
Immunohistochemistry and morphologic analysis are core cancer-pathology tools at NeoGenomics, Inc., helping classify tissue and guide diagnosis in routine tumor workups. They fit a mature market, so the service line is more of a steady cash generator than a high-growth bet. Their place in the lab flow also supports efficient throughput and repeat volume.
- Foundational in cancer diagnosis
- High routine-use volume
- Operationally efficient lab fit
- Mature, cash-flow style segment
NeoGenomics’ Cash Cows Keep the Oncology Lab Engine Running
NeoGenomics, Inc.’s Cash Cows are its mature clinical lab lines: Clinical Services generated about $615 million in FY2024 revenue, while FISH, cytogenetics, flow cytometry, and immunohistochemistry keep steady repeat volume. These are low-growth but essential oncology tests, so they support cash flow and lab utilization more than expansion.
| Cash Cow | Role | FY2024 data |
|---|---|---|
| Clinical Services | Core cash engine | $615 million |
| FISH, cytogenetics, flow, IHC | Recurring mature volume | Steady demand |
What You See Is What You Get
NeoGenomics, Inc. Reference Sources
You’re previewing the exact NeoGenomics, Inc. BCG Matrix document you’ll receive after purchase. The full file is the same professionally formatted report—no sample pages, no watermarks, and no hidden content. Once purchased, it’s instantly ready for download, editing, printing, or presentation.
Dogs
Legacy manual karyotyping
Legacy manual karyotyping at NeoGenomics, Inc. is a low-growth, low-share Dog. It is slower and less scalable than NGS-based diagnostics, so volume can slip as labs shift to faster molecular tests. NeoGenomics, Inc. still offers the method, but the strategic weight is limited versus higher-growth genomic assays.
Standalone routine pathology workups
Standalone routine pathology workups are a Dogs business for NeoGenomics, Inc. because morphology-only tests are highly commoditized and face heavy price pressure. They lack the deeper clinical differentiation of NeoGenomics, Inc.’s oncology menu, so pricing power is weak and growth tends to stay thin. In BCG terms, this is a low-share, low-growth area that usually earns little strategic capital.
Low-volume single-gene assays
Low-volume single-gene assays fit NeoGenomics, Inc.'s Dogs bucket: they are low-growth, low-share tests that are being squeezed by broader multiplex panels. These small assays usually add little incremental margin and face heavy price pressure from larger lab menus. As panels keep taking share, this line looks increasingly isolated and hard to scale.
Small non-core lab footprints
NeoGenomics, Inc.'s small non-core lab footprints fit the Dogs box because they usually sit outside the main U.S. oncology network and are hard to scale. If sample volumes stay thin, these sites add little margin and can drain cash instead of supporting growth.
- Low volume limits fixed-cost absorption
- Weak strategic fit outside core oncology
- Higher risk of cash drag
In 2025, this kind of footprint matters less than the core lab base, since oncology testing scale drives better utilization and return on invested capital. Small sites only help if they lift throughput fast; otherwise, they are maintenance costs, not growth assets.
Custom one-off research projects
Custom one-off research projects fit the Dog profile because NeoGenomics, Inc. must spend technical labor on ad hoc testing that is hard to standardize and rarely repeats. When demand is irregular, these jobs drain lab capacity but do not build durable share or recurring revenue.
- Low repeat volume
- Hard to standardize
- Consumes technical resources
- No durable share gain
NeoGenomics’ Dogs: Legacy Tests Draining Capital, Not Growing Value
NeoGenomics, Inc.'s Dogs are legacy, low-share, low-growth tests: manual karyotyping, morphology-only workups, single-gene assays, small non-core sites, and ad hoc research projects. These lines face weak pricing power, thin repeat volume, and poor scale, so they absorb capacity without much margin lift. In 2025, capital should stay with higher-growth oncology panels and NGS.
| Dog area | Why it lags |
|---|---|
| Legacy tests | Low growth, commoditized |
| Small sites/projects | Low volume, cash drag |
Question Marks
Digital pathology and AI analytics
Digital pathology and AI analytics are a clear Question Mark for NeoGenomics, Inc. because the segment is scaling fast in cancer diagnostics, but NeoGenomics’ share is still small. Its pathology workflow gives it a real route in, yet the market needs more software, data, and lab investment before it can turn into a cash generator.
Europe expansion
Europe is a question mark for NeoGenomics, Inc.: the business is present there, but scale is still far below the U.S. The region has real upside, with Europe seeing roughly 4.7 million new cancer cases a year and rising demand for oncology testing. Still, NeoGenomics’ competitive position is early, so growth is possible but not yet proven.
Asia expansion
Asia is a big question mark for NeoGenomics, Inc. because the region carries about 60% of global cancer cases, so the long-run oncology testing pool is huge.
NeoGenomics has a footprint there, but its share is still small versus stronger local and global rivals, which keeps revenue capture limited.
If it can win on turnaround time, payer access, and lab reach, Asia could shift from question mark to star; if not, growth stays optional.
Inivata alliance commercialization
NeoGenomics’ Inivata alliance sits in the question mark bucket because it opens a path into liquid biopsy, but adoption is still early and scale is not proven. The commercial upside is real, yet the business has not shown dominant traction or a clear near-term cash engine.
High growth potential
Low certainty on scale
Early commercialization only
New companion diagnostic launches
New companion diagnostics are a clear Question Mark for NeoGenomics, Inc.: they can ride with targeted cancer drugs, but each assay still needs adoption by oncologists and pharma partners. The opportunity is real, yet volume often starts small and stays uneven until a launch gains trust and repeat use.
That makes returns hard to predict in the early phase, even when the drug pipeline is strong. In NeoGenomics, Inc.’s case, these launches can win work, but the business only shifts toward a Star once test volumes and reimbursement both mature.
- Strong drug tie-ins, but slow adoption.
- Partnership wins do not ensure volume.
- Early launches stay cash-uncertain.
NeoGenomics’ Global Growth Bets: Huge Demand, Early Scale
NeoGenomics, Inc. question marks are high-growth bets with low current share: digital pathology and AI, Europe, Asia, Inivata, and new companion diagnostics. Asia holds about 60% of global cancer cases, and Europe sees about 4.7 million new cases a year, but NeoGenomics’ scale there is still early.
| Area | Signal |
|---|---|
| Asia | Huge demand, small share |
| Europe | 4.7M cases, early scale |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.